New advances in class III antiarrhythmic drug therapy

Current Opinion in Cardiology

Volumn 15, Issue 1, 2000, Pages 41-53

  Sager, Philip T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; DOFETILIDE; DRONEDARONE; IBUTILIDE; SOTALOL; TEDISAMAL; TEDISAMIL; TRECETILIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATOR; DOUBLE BLIND PROCEDURE; FEMALE; FOOD AND DRUG ADMINISTRATION; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART SURGERY; HEART VENTRICLE ARRHYTHMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINUS RHYTHM; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ELECTROPHYSIOLOGY; HUMANS; IMIDAZOLES; IMIDAZOLIDINES; PHENETHYLAMINES; PIPERAZINES; SOTALOL; SULFONAMIDES;

EID: 0033979447     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200001000-00006     Document Type: Review

References (95)

1. 1 Sager PT: New advances in class III antiarrhythmic drug therapy. Curr Opin Cardiol 1999, 14:15-23.
2. 2 Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991, 324:781-788.
3. 3 Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992, 20:527-532.
4. 4 Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990, 82:1106-1116.
5. 5 Boriani G, Biffi M, Capucci A, Botto GL, Broffoni T, Rubino I, et al.: Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial. Ann Intern Med 1997, 126:621-625.
6. 6 Lee SH, Chen SA, Tai CT, Chiang CE, Wen ZC, Chen YJ, et al.: Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. Am J Cardiol 1997, 79:905-908.
7. 7 Aliot E, Denjoy I: Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. Am J Cardiol 1996, 77:66A-71A.
8. 8 Naccarelli GV, Dorian P, Hohnloser SH, Coumel P: Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. Am J Cardiol 1996, 77:53A-59A.
9. 9 Julian DG, Jackson FS, Szekely P, Prescott RJ: A controlled trial of sotalol for 1 year after myocardial infarction. Circulation 1983, 67:161-162.
10. 10 Pacifico A, Hohnloser SH, Williams JH, Tao B, Saksena S, Henry PD, Prystowsky EN: Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med 1999, 340:1855-1862. This important study examines the effect of sotalol on ICD shock frequency and VT/VF recurrence.
11. 11 Sim I, McDonald KM, Lavori PW, Norbutas CM, Hlatky MA: Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation 1997, 96:2823-2829.
12. 12 Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P: Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997, 349:667-674.
13. 13 Cairns JA, Connolly SJ, Roberts R, Gent M: Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997, 349:675-682.
14. 14 Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997, 350:1417-1424.
15. 15 Ferguson J: Clinical trials. Clin Cardiol 1998, 21:51-54.
16. 16 DIAMOND MI Trial. AHA 1997 Scientific Sessions 1998 [oral presentation].
17. 17 Girouard SD, Pastore JM, Laurita KR, Gregory KW, Rosenbaum DS: Optical mapping in a new guinea pig model of ventricular tachycardia reveals mechanisms for multiple wavelengths in a single reentrant circuit. Circulation 1996, 93:603-613.
18. 18 Nattel S: The molecular and ionic specificity of antiarrhythmic drug actions. J Cardiovasc Electrophysiol 1999, 10:272-282. This is an excellent review of antiarrhythmic drug action.
19. 19 Nattel S, Liu L, St-Georges D: Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc Res 1998, 37:627-635.
20. 20 Jurkiewicz NK, Sanguinetti MC: Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ Res 1993, 72:75-83.
21. 21 Sager FT, Nademanee K, Antimisiaris M, Pacifico A, Pruitt C, Godfrey R, Singh BN: Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans. Circulation 1993, 88:1072-1082.
22. 22 Naccarelli GV, Wolbrette DL, Dell'Orfano JT, Patel HM, Luck JC: A decade of clinical trial developments in postmyocardial infarction, congestive heart failure, and sustained ventricular tachyarrhythmia patients: from CAST to AVID and beyond. Cardiac Arrhythmic Suppression Trial. Antiarrhythmic Versus Implantable Defibrillators. J Cardiovasc Electrophysiol 1998, 9:864-891. This is an excellent review of recent clinical arrhythmic trials.
23. 23 Mason JW: A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med 1993, 329:452-458.
24. 24 Kuhlkamp V, Mewis C, Mermi J, Bosch RF, Seipel L: Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. J Am Coll Cardiol 1999, 33:46-52.
25. 25 Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N: Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990, 82:1932-1939.
26. 26 Antman EM, Beamer AD, Cantillon C, McGowan N, Friedman PL: Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990, 15:698-707.
27. 27 Wanless RS, Anderson K, Joy M, Joseph SP: Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J 1997, 133:441-446.
28. 28 Benditt D, Williams JH, Jin J, Deering T, Zucker R, Browne KF, et al.: Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation/atrial flutter. Am J Cardiol 1999, 84:270-277. This study examined the optimal dosing of sotalol in patients with atrial fibrillation.
29. 29 Marcus FI: Risks of initiating therapy with sotalol for treatment of atrial fibrillation. J Am Coll Cardiol 1998, 32:177-180.
30. 30 Naccarelli GV, Jalal S: Intravenous amiodarone. Another option in the acute management of sustained ventricular tachyarrhythmias [editorial]. Circulation 1995, 92:3154-3155.
31. 31 Desai AD, Chun S, Sung RJ: The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med 1997, 127:294-303.
32. 32 Kowey PR, Marinchak RA, Rials SJ, Filart RA: Intravenous amiodarone. J Am Coll Cardiol 1997, 29:1190-1198.
33. 33 Levine JH, Massumi A, Scheinman MM, Winkle RA, Platia EV, Chilson DA, et al.: Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol 1996, 27:67-75.
34. 34 Scheinman MM, Levine JH, Cannom DS, Friehling T, Kopelman HA, Chilson DA, et al.: Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995, 92:3264-3272.
35. 35 Kudenchuk PJ, Cobb LA, Copass MK, Cummins RO, Doherty AM, Fahrenbruch CE, et al.: Amiodarone for resuscitation after out-of-hosptial cardiac arrest due to ventricular fibrillation. N Engl J Med 1999, 341:871-878. This study examined intravenous amiodarone in patients with out-of-hospital cardiac arrest.
36. 36 Nanas JN, Mason JW: Pharmacokinetics and regional electrophysiological effects of intracoronary amiodarone administration. Circulation 1995, 91:451-461.
37. 37 Du XJ, Esler MD, Dart AM: Sympatholytic action of intravenous amiodarone in the rat heart. Circulation 1995, 91:462-470.
38. 38 Haikerwal D, Dart AM, Little PJ, Kaye DM: Identification of a novel, inhibitory action of amiodarone on vesicular monoamine transport. J Pharmacol Exp Ther 1999, 288:834-837.
39. 39 Kavesh NG, Olsovsky MR, Freudenberger RS, Conte JV, Peters RW, Shorofsky SR, Gold MR: Intravenous amiodarone suppression of electrical storm refractory to chronic oral amiodarone. Pacing Clin Electrophysiol 1999, 22:665-667.
40. 40 Boutitie F, Boissel JP, Connolly SJ, Camm AJ, Cairns JA, Julian DG, et al.: Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 1999, 99:2268-2275.
41. 41 Sager PT, Behboodikah M, Ahmed R, Follmer CH: Frequency-dependent effects of beta-adrenergic stimulation on ventricular repolarizafion, refractoriness, and conduction in humans [abstract]. J Am Coll Cardiol 1994, 23:371.
42. 42 Sanguinetti MC, Jurkiewicz NK, Scott A, Siegl PK: Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes. Mechanism of action. Circ Res 1991, 68:77-84.
43. 43 Naccarelli GV, Lee KS, Gibson JK, Vander LJ: Electrophysiology and pharmacology of ibutilide. Am J Cardiol 1996, 78:12-16.
44. 44 Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, Vander LJ: Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996, 94:1613-1621.
45. 45 Ellenbogen KA, Stambler BS, Wood MA, Sager PT, Wesley RCJ, Meissner MC, et al.: Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996, 28:130-136.
46. 46 Lee KS: Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na+ current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992, 262:99-108.
47. 47 Lee KS, Tsai TD, Lee EW: Membrane activity of class III antiarrhythmic compounds; a comparison between ibutilide, d-sotalol, E-4031, sematilide and dofetilide. Eur J Pharmacol 1993, 234:43-53.
48. 48 Lynch JJJ, Baskin EP, Nutt EM, Guinosso PJJ, Hamill T, Salata JJ, Woods CM: Comparison of binding to rapidly activating delayed rectifier K+ channel, IKr, and effects on myocardial refractoriness for class III antiarrhythmic agents. J Cardiovasc Pharmacol 1995, 25:336-340.
49. 49 Wesley RCJ, Farkhani F, Morgan D, Zimmerman D: Ibutilide: enhanced defibrillation via plateau sodium current activation. Am J Physiol 1993, 264:H1269-H1274.
50. 50 Labhasetwar V, Underwood T, Heil RWJ, Gallagher M, Langberg J, Levy RJ: Epicardial administration of ibutilide from polyurethane matrices: effects on defibrillation threshold and electrophysiologic parameters. J Cardiovasc Pharmacol 1994;24:826-840.
51. 51 Khoury DS, Assar MD, Sun H: Pharmacologic enhancement of atrial electrical defibrillation efficacy: role of ibutilide. J Interventional Cardiac Electrophysiology 1997, 1:291-298.
52. 52 Oral H, Souza JJ, Michaud GF, Knight BP, Goyal R, Strickberger SA, Morady F: Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999, 340:1849-1854. This study examined the efficacy of ibutilide in reducing the atrial defibrillation threshold.
53. 53 Glatter KACK, Huang S, Cheng J, Kayser SSMM: Is it safe to use intravenous ibutilide in patients receiving chronic amiodarone therapy? [abstract] Circulation (Suppl) 1998, 98:I-1-I-1016.
54. 54 Aranki SF, Shaw DP, Adams DH, Rizzo RJ, Couper GS, Vander VM, et al.: Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation 1996, 94:390-397.
55. 55 Guarnieri T, Nolan S, Gottlieb SO, Dudek A, Lowry DR: Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) Trial. J Am Coll Cardiol 1999, 34:343-347. This study evaluated the role of intravenous amiodarone in decreasing postoperative atrial fibrillation.
56. 56 Hohnloser SH, Meinertz T, Dammbacher T, Steiert K, Jahnchen E, Zehender M, et al.: Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: results of a prospective, placebo-controlled study. Am Heart J 1991, 121:89-95.
57. 57 Daoud EG, Strickberger SA, Man KC, Goyal R, Deeb GM, Bolling SF, et al.: Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med 1997, 337:1785-1791.
58. 58 Gomes JA, Ip J, Santoni-Rugiu F, Mehta D, Ergin A, Lansman S, et al.: Oral d,l sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1999, 34:334-339. This study evaluated the role of intravenous sotalol in decreasing postoperative atrial fibrillation.
59. 59 Parikka H, Toivonen L, Heikkila L, Virtanen K, Jarvinen A: Comparison of sotalol and metoprolol in the prevention of atrial fibrillation after coronary artery bypass surgery. J Cardiovasc Pharmacol 1998, 31:67-73.
60. 60 Vanderlugt J, Mattioni T, Denker S, Torchiana D, Ahern T, Wakefield LK, et al.: Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. Circulation 1999, 100:369-375. This study evaluated the efficacy of ibutilide in terminating postoperative atrial fibrillation.
61. 61 Ellenbogen KA, Stambler BS, Wood MA, Sager PT, Wesley RCJ, Meissner MC, et al.: Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996, 28:130-136.
62. 62 Sager PT: The frequency-dependent effects of dofetilide in humans [abstract]. Circulation 1995, 92II:774.
63. 63 Nademanee K, Bailey W, O'Neill G, Satler C, Freidrich T: Electrophysiologic and hemodynamic effects of dofetilide in patients with left ventricular function: a randomized, double-blind, placebo-controlled study [abstract]. PACE 1998, In press.
64. 64 Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, et al.: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigation of Arrhythmia and Mortality on Dofetilide Sudy Group. N Engl J Med 1999, 341:857-865.
65. 65 Waldo AL, Camm AJ, de Ruyter H, Friedman PL, MacNeil DJ, Pauls JF, et al.: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996, 348:7-12.
66. 66 Dalrymple H, Campbell T, Channer K, Kingma J, Greenbaum R, Santini M, et al.: Maintenance of sinus rhythm by dofetilide improves quality of life. The EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) Study [abstract]. Circulation (Suppl) 1998, 98:1-13.
67. 67 Singh S, Berk M, Yellen L, Zoble R, Haley J, Abrahamson D, et al.: Efficacy and safety of oral dofetilide in maintaining normal sinus in patients with atrial fibrillation/flutter: a multicenter study [abstract]. Circulation (Suppl) 1997, 96:1383.
68. 68 Singh S, Berk M, Yellen L, Abrahamson D: Restoration and maintenance of sinus rhythm reduces frequency and severity of symptoms associated with atrial fibrillation and flutter [abstract]. PACE 1998, In press.
69. 69 Falk RH, Pollak A, Singh SN, Friedrich T: Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol 1997, 29:385-390.
70. 70 Pedersen O, The DIAMOND Study Group: Dofetilide in the treatment of atrial fibrillation in patients with impaired left ventricular function: atrial fibrillation in the DIAMOND Study [abstract]. Circulation (Suppl) 1998, 98:1-633.
71. 71 Fermini B, Jurkiewicz NK, Jow B, Guinosso PJJ, Baskin EP, Lynch JJJ, Salata JJ: Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 1995, 26:259-271.
72. 72 Salata J, Brooks R: Pharmacology of azimilide dihydrochloride (NE-10064), A Class III antiarrhythmic agent. Cardiovasc Drug Rev 1997, 15:137-156.
73. 73 Nair LA, Grant AO: Emerging class III antiarrhythmic agents: mechanism of action and proarrhythmic potential. Cardiovasc Drugs Ther 1997, 11:149-167.
74. 74 Sager PT: Modulation of antiarrhythmic drug effects by beta-adrenergic sympathetic stimulation. Am J Cardiol 1998;82:20I-30I.
75. 75 Drexler AP, Micklas JM, Brooks RR: Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction. J Cardiovasc Pharmacol 1996, 28:848-855.
76. 76 Karam R, Marcello S, Brooks RR, Corey AE, Moore A: Azimilide dihydrochloride, a novel antiarrhythmic agent. Am J Cardiol 1998, 81:40D-46D.
77. 77 Corey A, Agnew J, Bao J, Bryson P, Comer P, Griffith S, Li J: Effect of age and gender on azimilide pharmacokinetics after a single oral dose of azimilide dihydrochloride. J Clin Pharmacol 1997, 37:946-953.
78. 78 Corey AE, Al-Khalidi H, Brezovic C, Marcello S, Parekh N, Taylor K, Karam R: Azimilide pharmacokinetics after a single oral dose of azimilide dihydrochloride [abstract]. J Clin Pharmacol 1997, 37:946-953.
79. 79 Pritchett E, Connolly S, Page R, Marcello SSD, Wilkinson W: Survival in patients treated with azimilide for atrial fibrillation and other supraventricular arrhythmias [abstract]. Eur Heart J 1999.
80. 80 Connelly S, Page R, Marcello S, Schnell D, Wilkinson W, Pritchett E: Dose response of azimilide for prevention of atrial fibrillation or flutter [abstract]. Eur Heart J 1999.
81. 81 Pritchett E, Page P, Connelly S, Marcello S, Schnell D, Wilkinson WE: Azimilide treatment in atrial fibrillation. Circulation (Suppl) 1999, 98:1633.
82. 82 Page RL, Connolly S, Marcello S, Schnell D, Wilkinson W, Pritchett E: Dose response for azimilide treatment of paroxysmal supraventricular tachycardia [abstract]. Eur Heart J 1999.
83. 83 Camm AJ, Karam R, Pratt CM: The azimilide post-infarct survival evaluation (ALIVE) trial. Am J Cardiol 1998, 81:35D-39D.
84. 84 Manning AS, Bruyninckx C, Ramboux J, Chatelain P: SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. J Cardiovasc Pharmacol 1995, 26:453-461.
85. 85 Chatelain P, Meysmans L, Matteazzi JR, Beaufort P, Clinet M: Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart. Br J Pharmacol 1995, 116:1949-1956.
86. 86 Hodeige D, Heyndrickx JP, Chatelain P, Manning A: SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs. Eur J Pharmacol 1995, 279:25-32.
87. 87 Manning A, Thisse V, Hodeige D, Richard J, Heyndrickx JP, Chatelain P: SR 33589, a new amiodarone-like antiarrhythmic agent: electrophysiological effects in anesthetized dogs. J Cardiovasc Pharmacol 1995, 25:252-261.
88. 88 Finance O, Manning A, Chatelain P: Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. J Cardiovasc Pharmacol 1995, 26:570-576.
89. 89 Friedrichs GS, Abreu JN, Driscoll EMJ, Borlak J, Lucchesi BR: Antifibrillatory efficacy of long-term tedisamil administration in a postin-farcted canine model of ischemic ventricular fibrillation. J Cardiovasc Pharmacol 1998, 31:56-66.
90. 90 Chi L, Park JL, Friedrichs GS, Banglawala YA, Perez MA, Tanhehco EJ, Lucchesi BR: Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart. Br J Pharmacol 1996, 117:1261-1269.
91. 91 Wettwer E, Himmel HM, Amos GJ, Li Q, Metzger F, Ravens U: Mechanism of block by tedisamil of transient outward current in human ventricular subepicardial myocytes. Br J Pharmacol 1998, 125:659-666.
92. 92 Bargheer K, Bode F, Klein HU, Trappe HJ, Franz MR, Lichtlen PR: Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent. Eur Heart J 1994, 15:1409-1414.
93. 93 Fedida D, Wible B, Wang Z, Fermini B, Faust F, Nattel S, Brown AM: Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current. Circ Res 1993, 73:210-216.
94. 94 Yue L, Feng J, Li GR, Nattel S: Characterization of an ultrarapid delayed rectifier potassium channel involved in canine atrial repolarization. J Physiol (Lond) 1996, 496:647-662.
95. 95 Feng J, Xu D, Wang Z, Nattel S: Ultrarapid delayed rectifier current inactivation in human atrial myocytes: properties and consequences. Am J Physiol 1998, 275:H1717-H1725.